MY ACCOUNT | NEWSLETTER |

The combination of Massachusetts type vaccine viruses with QX or 4/91 vaccine variants induce protection against a challenge with QX or 793B type field viruses


Many different genotypes of infectious bronchitis virus circulate in Europe in chickens and turkeys. A common control strategy to prevent the consequences of infection is vaccination with live attenuated vaccines. With it, protection against the homologous strains used and cross-protection against virulent heterologous strains are sought as an additional value. In this work, two typical Massachusetts+variant vaccine combinations were evaluated as valid to develop protection against the challenge of virulent strains frequently circulating in the field.

Vaccination plans with combinations of different infectious bronchitis (IB) vaccine virus serotypes may protect against challenge with field viruses for which there are no homologous vaccine viruses. Live attenuated H120 vaccines are safe and efficacious against Massachusetts-type viruses and provide strong protection against homologous challenge and variable protection against heterologous challenge. Live attenuated vaccines have been developed with variant strains that protect against challenges with homologous strains and offer some degree of cross-protection against other heterologous strains.

Combining live attenuated IB vaccines on the day of birth makes it possible to stimulate and amplify actively acquired immunity against field strains homologous and heterologous to those of the applied vaccines. Vaccination on the first day of life in the hatchery is more cost-effective compared to programs that are applied during the first weeks of life.

In the present study, cross-protection against challenge with a type 793B strain after vaccination with a combination of the H120 and type QX strains was evaluated. A QX-like field virus challenge was also included. In addition, the efficacy of a combination of IBV vaccine strains Ma5 and 4/91 against challenge with these same viruses was tested. At the time of challenge, samples were taken to determine antibody titers against IB virus. Five days later, ciliostasis was evaluated as a measure of efficacy.


J. Boelm + JJ de Wit, “The combination of Massachusetts type vaccine viruses with QX or 4/91 vaccine variants induce protection against a challenge with QX or 793B type field viruses.” J Avium No. 3, September 2022.




Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Clinical, radiographic and histologic evaluation of cystic oral lesions in cats

Like0
Dislike0

Splenectomy in the management of primary immune-mediated hematological diseases

Like0
Dislike0

Morris Animal Foundation Golden Retriever Lifetime Study celebrates 10 years

Like0
Dislike0

Study looks at effects of lameness on productivity, longevity for sows in pen gestation in Sweden

Like0
Dislike0

Review of clinical management of feline leishmaniosis

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2022 - All Rights Reserved
ISSN 2768-198X

Top